Laboratorio CRIMM - Centro di Ricerca e Innovazione delle Malattie Mieloproliferative
Laboratorio CRIMM - Centro di Ricerca e Innovazione delle Malattie Mieloproliferative is recorded as a service provider in 2 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 2 of 2 trials · Latest update first
A Phase 3, prospective, randomized, multi-center, intervention trial of early intensification in AML patients bearing FLT3 mutations based on peripheral blast clearance. A MYNERVA-GIMEMA study. AMELIORATE (AML Early IntensificatiOn based on peRipheral blAsT clEarance). AML1919
Sponsor Fondazione Gimema Franco Mandelli Onlus
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase 2, prospective, multi-center intervention trial in patients with acute myeloid leukemia secondary to myeloproliferative neoplasms unfit for intensive chemotherapy investigating a treatment combination including decitabine and venetoclax. ENABLE (vENetoclax plus decitAbine treatment in Blastic phase of myeLoproliferative nEoplasms). AML2420
Sponsor Fondazione Gimema Franco Mandelli Onlus
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Laboratorio CRIMM - Centro di Ricerca e Innovazione delle Malattie Mieloproliferative?
The 2026-10-09 snapshot links Laboratorio CRIMM - Centro di Ricerca e Innovazione delle Malattie Mieloproliferative to 2 distinct CTIS trials. Recorded services include Laboratory services. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Laboratorio CRIMM - Centro di Ricerca e Innovazione delle Malattie Mieloproliferative?
Therapeutic-area tags are not recorded in this snapshot. Study-phase tags are not recorded. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Laboratorio CRIMM - Centro di Ricerca e Innovazione delle Malattie Mieloproliferative conducted?
The linked trials record locations in 1 country, including Italy. These are trial locations, not confirmed office locations or countries where Laboratorio CRIMM - Centro di Ricerca e Innovazione delle Malattie Mieloproliferative delivered services.
What can this page tell me about Laboratorio CRIMM - Centro di Ricerca e Innovazione delle Malattie Mieloproliferative's trial experience?
Browse 2 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Laboratorio CRIMM - Centro di Ricerca e Innovazione delle Malattie Mieloproliferative. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Laboratorio CRIMM - Centro di Ricerca e Innovazione delle Malattie Mieloproliferative